T. Vieler

Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial

R. Greil, H. Eich, R. Semrau, 2015, The Lancet.

Mobiler Konsiliardienst HIV/AIDS in Schleswig-Holstein

T. Vieler, G. Petersen, M. Corzillius, 2000 .

PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial.

R. Greil, H. Eich, V. Diehl, 2021, The Lancet. Haematology.

Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase

K. Döhner, T. Haferlach, J. Panse, 2017, Annals of Hematology.

Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: an analysis of the german hodgkin study group.

V. Diehl, U. Dührsen, P. Borchmann, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group

R. Greil, H. Eich, V. Diehl, 2017, The Lancet.

Rash-associated severe neutropenia as a side-effect of indinavir in HIV postexposure prophylaxis.

H. Horst, T. Vieler, D. Albrecht, 2002, AIDS.

Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial

R. Greil, H. Eich, R. Semrau, 2015, The Lancet.